文献速递外周动脉疾病

每日步数达标与跛行患者步行功能及生活质量的相关性

Association between meeting daily step count goals with ambulatory function and quality of life in patients with claudication.
PubMed 文献 · J Vasc Surg · 2020-11-27

结果显示步数≥7000步的两组6MWD和WIQ距离评分均高于<7000步组,且校正协变量后差异仍显著。

要点

  • 每日步数≥7000步的PAD跛行患者6MWD和WIQ距离评分显著高于<7000步者。
  • 步数达标带来的步行功能和生活质量优势在校正年龄、性别、体重及合并症后仍存在。
  • 研究提供初步证据支持以7000步/日作为PAD患者步行获益的参考阈值。

核心结论

  • PAD跛行患者每日步行≥7000步或≥10000步者,其步行功能和健康相关生活质量优于每日<7000步者。
  • 校正协变量后,每日7000步和10000步对应的步行功能及生活质量优势仍持续存在。

研究设计与样本

  • 按每日步数分为三组:<7000步组(n=153)、7000-9999步组(n=57)、≥10000步组(n=38)。
  • 主要结局为6分钟步行距离(6MWD)和步行损害问卷(WIQ)距离评分。

主要发现

  • 三组间踝肱指数(P=.02)、高血压(P=.04)、糖尿病(P<.01)、腹部肥胖(P<.01)、关节炎(P=.04)和慢性阻塞性肺疾病(P<.01)患病率存在显著差异。
  • 未校正分析中三组6MWD差异显著(P<.01),组1为313±90 m,组2为378±84 m,组3为414±77 m;组2和组3高于组1(P<.01)。
  • 校正分析中三组6MWD差异仍显著(P<.01)。
  • 未校正分析中三组WIQ距离评分差异显著(P<.01),组1为30±30%,组2为45±35%,组3为47±34%;组2和组3高于组1(P<.01)。
  • 校正分析中三组WIQ距离评分差异仍显著(P<.01)。

临床怎么用

  • 临床评估PAD跛行患者时,可将每日步数作为步行功能和生活质量的简易参考指标。
  • 每日步数<7000步可能提示步行功能和生活质量较差,需加强干预。
  • 鼓励患者每日步行达到7000步以上可能有助于改善步行能力和生活质量,但需进一步研究验证。

局限性

  • 研究为观察性设计,无法确定步数与步行功能及生活质量之间的因果关系。
  • 研究提供的是初步证据,步数阈值与临床获益的关系需更深入研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine (a) whether patients with peripheral artery disease (PAD) who walked at least 7000 and 10,000 steps/day had better ambulatory function and health-related quality of life (HRQoL) than patients who walked less than 7000 steps/day, and (b) whether differences in ambulatory function and HRQoL in patients grouped according to these daily step count criteria persisted after adjusting for covariates. METHODS: Two hundred forty-eight patients were assessed on their daily ambulatory activity for 1 week with a step activity monitor, and were grouped according to daily step count targets. Patients who took fewer than 7000 steps/day were included in group 1 (n = 153), those who took 7000 to 9999 steps/day were included in group 2 (n = 57), and patients who took at least 10,000 steps/day were included in group 3 (n = 38). Primary outcomes were the 6-minute walk distance (6MWD) and Walking Impairment Questionnaire (WIQ) distance score, which is a disease-specific measurement of HRQoL. Patients were further characterized on demographic variables, comorbid conditions, and cardiovascular risk factors. RESULTS: The groups were significantly different on ankle-brachial index (P = .02), and on the prevalence of hypertension (P = .04), diabetes (P < .01), abdominal obesity (P < .01), arthritis (P = .04), and chronic obstructive pulmonary disease (P < .01). Thus, these variables served as covariates in adjusted analyses, along with age, weight, and sex. The 6MWD (mean ± standard deviation) was significantly different among the groups in unadjusted (P < .01) and adjusted (P < .01) analyses (group 1, 313 ± 90 m; group 2, 378 ± 84 m; and group 3, 414 ± 77 m), with groups 2 and 3 having a higher 6MWD than group 1 (P < .01). The WIQ distance score was significantly different among the groups in unadjusted (P < .01) and adjusted (P < .01) analyses (group 1, 30 ± 30%; group 2, 45 ± 35%; and group 3, 47 ± 34%), with groups 2 and 3 having higher WIQ distance scores than group 1 (P < .01). CONCLUSIONS: Patients with PAD who walked more than 7000 and 10,000 steps/day had greater ambulatory function and HRQoL than patients who walked fewer than 7000 steps/day. Second, the greater ambulatory function and HRQoL associated with walking 7000 and 10,000 steps/day persisted after adjusting for covariates. This study provides preliminary evidence that patients with PAD who walk more than 7000 steps/day have better ambulatory function and HRQoL than patients below this threshold.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gardner AW, Montgomery PS, Wang M, et al. Association between meeting daily step count goals with ambulatory function and quality of life in patients with claudication. J Vasc Surg. 2020. PMID: 33253870. doi:10.1016/j.jvs.2020.10.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。